[1] [2] Las directrices de la American Diabetes Association (ADA) establecen que los agonistas GLP-1 constituyen una terapia crnica para el manejo de la diabetes tipo 2
Although the research is promising, there are many factors that could potentially impact depression among people with obesity who are taking these medications (weight loss, physical activity, less medical burden, nutritional status, hopefulness, sleep, etc). Semaglutide and tirzepatide were the two medications most strongly related to decreased risk of depression and anxiety
The studys insights, consistent with those from previous clinical trials, are important additional information for clinicians and policymakers aiming to optimize therapy for patients with T2D and enhance diabetes management strategies
Pilot Programs and Monitoring: Carefully designed pilot programs allow for data gathering, impact measurement, and strategic adjustments